PTC Therapeutics prices USD 550 million zero-coupon convertible notes due 2031

By Public Technologies
  • PTC Therapeutics closed a private offering of USD 550 million 0.0% convertible senior notes due 2031.
  • Deal size includes the full exercise of an option for an additional USD 50 million principal amount.
  • Notes carry no regular interest and mature June 15, 2031, unless converted, redeemed, or repurchased earlier.
  • Initial conversion price about USD 107.48 per share, equivalent to 9 shares per USD 1,000 principal amount.
  • Redemption barred before June 20, 2029; callable thereafter if the stock trades at least 130% of the conversion price.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-075731), on June 18, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.